Medicare GLP-1 Bridge Program Explained: What We've Learned After the First Two Months

If you’ve been searching for information about Medicare coverage for Wegovy®, Zepbound®, or other GLP-1 weight loss medications, you’re not alone. Since Medicare’s GLP-1 Bridge Program launched on July 1, 2026, we’ve received a growing number of calls from Medicare beneficiaries trying to understand the same handful of questions: Do I qualify? Why are some people paying only $50? Why am I being told I don’t qualify? Why is my doctor’s office confused about the paperwork? And why is someone else getting the medication through the Bridge Program while I have to use my Part D plan?

After helping clients navigate the program over the past two months, I want to share what we’re seeing in the real world — not just what’s written in the CMS guidance.

What is the Medicare GLP-1 Bridge Program?

The Medicare GLP-1 Bridge Program is a temporary Centers for Medicare & Medicaid Services (CMS) program designed to help eligible Medicare beneficiaries access certain GLP-1 medications for obesity treatment. For beneficiaries who qualify, the medication is available for a $50 copay.

The program began July 1, 2026, and is currently scheduled to continue through December 31, 2027, while CMS develops a longer-term Medicare obesity medication model.

Unlike traditional Medicare Part D prescription drug coverage, the Bridge Program operates separately. That means:

• The $50 copay does not count toward your Medicare Part D deductible.
• The $50 copay does not count toward your annual Medicare Part D out-of-pocket drug costs.
• Manufacturer coupons and savings cards cannot be used.
• Claims are processed through the Medicare GLP-1 Bridge Program rather than your regular Medicare Part D plan.

One of the biggest misunderstandings

One misconception we’ve seen repeatedly is that any Medicare beneficiary who wants to lose weight can receive a GLP-1 medication for $50. Unfortunately, that isn’t how the program works.

The Bridge Program has specific medical eligibility requirements. Your physician must determine whether you meet those requirements and complete a Prior Authorization (PA) before coverage can be approved.

In other words: this isn’t simply a matter of asking your doctor for Wegovy or Zepbound. There is medical documentation that must be completed, submitted, and approved.

The prior authorization is one of the most important parts

One of the biggest updates since the program launched is that CMS released its official Prior Authorization form. This gives providers clear guidance on what medical information must be submitted before a patient can be approved.

If you’re interested in the Bridge Program, one of the most important conversations you can have is with your prescribing physician. Ask whether you may meet the medical criteria, and make sure the office is aware that the Medicare GLP-1 Bridge Program requires its own specific Prior Authorization.

You can find the official CMS information and Prior Authorization resources on the CMS GLP-1 Bridge Program page.

What we’re seeing after two months

Every patient’s situation is different, but two months in, several trends have become very clear.

1. Many doctor’s offices are still learning the process

This is a brand-new Medicare program. Some physicians and office staff have never completed a Medicare GLP-1 Bridge Program Prior Authorization before, and we’ve seen delays simply because offices weren’t familiar with the process or didn’t know additional documentation was required. Fortunately, awareness continues to improve.

2. Many people assume everyone qualifies

One of the most common misconceptions is that Medicare is now covering weight loss medications for everyone. That’s simply not true. Medical eligibility requirements still apply, and receiving a prescription does not automatically mean someone qualifies for the Bridge Program.

3. There is frustration over the different coverage pathways

One of the biggest points of confusion is that some Medicare beneficiaries receive GLP-1 medications through the Bridge Program while others receive them through their regular Medicare Part D plan.

For example, beneficiaries taking a GLP-1 for conditions already covered under Medicare Part D — such as Type 2 diabetes or certain other FDA-approved indications — generally continue to receive coverage through their Medicare prescription drug plan rather than the Bridge Program. Because of that, some people compare costs and wonder why someone using the Bridge Program pays $50 while their own costs may be different.

It’s understandable why people ask. The important thing to understand is that these are two separate Medicare coverage pathways created for different purposes.

4. We’ve also seen success

The good news is that we’ve helped clients successfully obtain medications through the Medicare GLP-1 Bridge Program. While the process isn’t always quick, successful approvals absolutely happen when patients meet the eligibility requirements and the required documentation is completed correctly.

Common reasons applications are delayed

If you’re applying through the Bridge Program, these are the most common issues we’ve seen:

• The doctor’s office isn’t familiar with the Medicare Bridge Program.
• The Prior Authorization is incomplete.
• Required medical documentation wasn’t submitted.
• The beneficiary doesn’t meet the clinical requirements.
• There is confusion between traditional Medicare Part D coverage and the Bridge Program.

Most of these issues can be resolved — but they often require patience and communication between the patient and the provider’s office.

What you should do if you’re interested

If you’re considering a GLP-1 medication through Medicare, here are a few recommendations:

1. Schedule an appointment with your healthcare provider.
2. Discuss whether you meet the medical criteria.
3. Ask whether your provider is familiar with the Medicare GLP-1 Bridge Program Prior Authorization.
4. Understand that approval is not automatic.
5. Be patient. Like any new Medicare program, there is a learning curve for providers, pharmacies, and beneficiaries.

Frequently asked questions

Does everyone on Medicare qualify? No. The program has medical eligibility requirements that must be met before approval.

Can my primary care physician complete the paperwork? Yes. The prescribing healthcare provider completes and submits the required Prior Authorization.

Is the medication really only $50? For beneficiaries who qualify and are approved through the Bridge Program, the current copay is $50.

Does the $50 count toward my Medicare Part D deductible? No. Because the Bridge Program operates separately from Medicare Part D, those payments do not count toward your deductible or annual out-of-pocket prescription drug costs.

Does this replace my Medicare Part D plan? No. The Bridge Program is completely separate from your Medicare prescription drug coverage.

Why work with Mere Benefits?

The Medicare GLP-1 Bridge Program has created a lot of excitement — but it’s also created a lot of confusion.

Our role isn’t to prescribe medications or determine whether you medically qualify. That’s between you and your healthcare provider. What we can do is help you understand how Medicare coverage works and help you navigate your options. We regularly help clients answer questions like:

• Should this medication go through the Bridge Program or my Medicare Part D plan?
• Am I enrolled in the Medicare plan that’s best for my prescriptions?
• Why was my medication denied?
• What information does my doctor’s office need?
• Is there another Medicare option that may better fit my needs?

Healthcare providers focus on your medical care. Pharmacies focus on filling prescriptions. Insurance companies administer benefits. At Mere Benefits, we focus on helping Medicare beneficiaries understand their coverage so they can make informed decisions.

Final thoughts

The Medicare GLP-1 Bridge Program has created new opportunities for eligible beneficiaries to access obesity medications that were previously unavailable or unaffordable for many people.

Like most new Medicare programs, there has been a learning curve. We’ve seen confusion, delays, questions, and frustration — but we’ve also seen successful approvals. As providers become more familiar with the process and CMS continues providing guidance, we expect the program to become easier to navigate. We’ll continue monitoring changes and sharing updates so Medicare beneficiaries have accurate, easy-to-understand information.

If you’re confused about Medicare prescription coverage or wondering how the GLP-1 Bridge Program applies to your situation, we’re happy to help explain your options. Call Mere Benefits at 904-654-5450 or reach out for a free, no-obligation review. We’re licensed in Florida, Arizona, California, Georgia, Maryland, Michigan, New Jersey, North Carolina, South Carolina, Texas, and Utah.

This article is intended for educational purposes only and should not be considered medical, legal, or tax advice. Eligibility for the Medicare GLP-1 Bridge Program is determined by CMS program requirements and your healthcare provider’s clinical assessment. Always consult your physician regarding medical treatment decisions. Mere Benefits is not connected with or endorsed by the U.S. government or the federal Medicare program.